Novo is fighting for a larger share of the obesity market as Wegovy weight-loss pill sales lift its outlook.
Novo raised its forecast for the year, citing sales of its Wegovy weight-loss pill. The boost comes as the company fights for a larger share of the obesity market.
—
6 Sources, first seen ago
The Economic Times reports Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected in India in the first half of 2027, and that top officials said both products have already been submitted to Indian regulators.
Bloomberg reports that the agreement covers rights to the Swedish company’s drug-delivery technology for obesity and diabetes treatments.
The Economic Times reports Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected in India in the first half of 2027, and that top officials said both products have already been submitted to Indian regulators.
Bloomberg reports that the agreement covers rights to the Swedish company’s drug-delivery technology for obesity and diabetes treatments.
#4
#4
@businessNovo boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share of the obesity market https://www.bloomberg.com/news/articles/2026-11-04/novo-boosts-forecast-as-wegovy-pill-beats-estimates?taid=6aeafd78c6a02200012fb4ae&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter
@MarketWatchBeleaguered Novo offers relief to investors, thanks to Wegovy pill https://www.marketwatch.com/story/beleaguered-novo-offers-relief-to-investors-thanks-to-wegovy-pill-422c251b?mod=dist_amp_social&link=sfmw_tw
@EmmanuelInvestThis is why I'm becoming increasingly constructive on Novo Nordisk $NVO. Wegovy pill momentum is improving, management has raised its full-year adjusted outlook, and shares are indicated around 5% higher pre-market. But the bigger story isn't today's share-price reaction. It's whether oral Wegovy can expand the obesity market, offset pricing pressure and help Novo return to sustainable earnings growth. Eli Lilly remains a serious competitor, and the recovery is far from complete. I remain bullish on the long-term opportunity. Novo doesn't need a perfect recovery. It needs a credible one.@businessNovo boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share of the obesity market https://www.bloomberg.com/news/articles/2026-11-04/novo-boosts-forecast-as-wegovy-pill-beats-estimates?taid=6aeafd78c6a02200012fb4ae&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@MarketWatchBeleaguered Novo offers relief to investors, thanks to Wegovy pill https://www.marketwatch.com/story/beleaguered-novo-offers-relief-to-investors-thanks-to-wegovy-pill-422c251b?mod=dist_amp_social&link=sfmw_tw@EmmanuelInvestThis is why I'm becoming increasingly constructive on Novo Nordisk $NVO. Wegovy pill momentum is improving, management has raised its full-year adjusted outlook, and shares are indicated around 5% higher pre-market. But the bigger story isn't today's share-price reaction. It's whether oral Wegovy can expand the obesity market, offset pricing pressure and help Novo return to sustainable earnings growth. Eli Lilly remains a serious competitor, and the recovery is far from complete. I remain bullish on the long-term opportunity. Novo doesn't need a perfect recovery. It needs a credible one.@businessNovo boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share of the obesity market https://www.bloomberg.com/news/articles/2026-11-04/novo-boosts-forecast-as-wegovy-pill-beats-estimates?taid=6aeafd78c6a02200012fb4ae&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@MarketWatchBeleaguered Novo offers relief to investors, thanks to Wegovy pill https://www.marketwatch.com/story/beleaguered-novo-offers-relief-to-investors-thanks-to-wegovy-pill-422c251b?mod=dist_amp_social&link=sfmw_tw@EmmanuelInvestThis is why I'm becoming increasingly constructive on Novo Nordisk $NVO. Wegovy pill momentum is improving, management has raised its full-year adjusted outlook, and shares are indicated around 5% higher pre-market. But the bigger story isn't today's share-price reaction. It's whether oral Wegovy can expand the obesity market, offset pricing pressure and help Novo return to sustainable earnings growth. Eli Lilly remains a serious competitor, and the recovery is far from complete. I remain bullish on the long-term opportunity. Novo doesn't need a perfect recovery. It needs a credible one.@businessNovo boosted its forecast for the year, citing sales of its Wegovy weight-loss pill as it continues to fight for a larger share of the obesity market https://www.bloomberg.com/news/articles/2026-11-04/novo-boosts-forecast-as-wegovy-pill-beats-estimates?taid=6aeafd78c6a02200012fb4ae&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter@MarketWatchBeleaguered Novo offers relief to investors, thanks to Wegovy pill https://www.marketwatch.com/story/beleaguered-novo-offers-relief-to-investors-thanks-to-wegovy-pill-422c251b?mod=dist_amp_social&link=sfmw_tw@EmmanuelInvestThis is why I'm becoming increasingly constructive on Novo Nordisk $NVO. Wegovy pill momentum is improving, management has raised its full-year adjusted outlook, and shares are indicated around 5% higher pre-market. But the bigger story isn't today's share-price reaction. It's whether oral Wegovy can expand the obesity market, offset pricing pressure and help Novo return to sustainable earnings growth. Eli Lilly remains a serious competitor, and the recovery is far from complete. I remain bullish on the long-term opportunity. Novo doesn't need a perfect recovery. It needs a credible one.
